Reaction Details Report a problem with these data
Target
Malignant T-cell-amplified sequence 1
Ligand
BDBM345299
Substrate
n/a
Meas. Tech.
Assay 4: MCT1-Mediated Lactate Transport in BT20 Breast Cancer Cells
IC50
12000±n/a nM
Citation
 Parnell, KM; McCall, J MCT4 inhibitors for treating disease US Patent  US10202350 Publication Date 2/12/2019 
Target
Name:
Malignant T-cell-amplified sequence 1
Synonyms:
MCT-1 | MCT1 | MCTS1 | MCTS1_HUMAN | Multiple copies T-cell malignancies
Type:
Enzyme Catalytic Domain
Mol. Mass.:
20563.62
Organism:
Homo sapiens (human)
Description:
n/a
Residue:
181
Sequence:
MFKKFDEKENVSNCIQLKTSVIKGIKNQLIEQFPGIEPWLNQIMPKKDPVKIVRCHEHIEILTVNGELLFFRQREGPFYPTLRLLHKYPFILPHQQVDKGAIKFVLSGANIMCPGLTSPGAKLYPAAVDTIVAIMAEGKQHALCVGVMKMSAEDIEKVNKGIGIENIHYLNDGLWHMKTYK
  
Inhibitor
Name:
BDBM345299
Synonyms:
2-[[1-[(2-Chlorophenyl)methyl]-5-[3- (tetrahydropyran-4- ylmethoxy)phenyl]pyrazol-3-yl]methoxy]- 2-methyl-propanoic acid. 1HNMR (CDCl3): $#948; 1.34-1.41 (m, 2H), 1.55 (s, 6H), 1.66-1.69 (m, 2H), 1.97- 1.99 (m, 1H), 3.38-3.46m, 2H), 3.56 (d, 2H), 3.98-4.01 (m, 2H), 4.62 (s, 2H), 5.42 (s, 2H), 6.42 (s, 1H), 6.71 (s, 1H), 6.77-6.95 (m, 3H), 7.19-7.35 (m, 4H). | US10202350, Example 45 | US10214492, Example 45 | US11292767, Example 45 | US11724989, Example 45
Type:
Small organic molecule
Emp. Form.:
C27H31ClN2O5
Mol. Mass.:
498.998
SMILES:
CC(C)(OCc1cc(-c2cccc(OCC3CCOCC3)c2)n(Cc2ccccc2Cl)n1)C(O)=O
Structure:
Search PDB for entries with ligand similarity: